Trial Profile
Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 04 Apr 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 12 Mar 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.